BioPharmSignal logoBioPharmSignal

Biotech News

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Adial Pharmaceuticals (ADIL)Adial PharmaceuticalsClinical readout

Engages with Cytel's Machine Learning Technology on Data Analysis and Phase 3 Trial Design

GLEN ALLEN, Va., June 11, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing precision treatments for...

Related news

ADILAdial Pharmaceuticals2024-11-14 08:30 EST

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

ADILAdial Pharmaceuticals2024-09-19 08:30 EST

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

View all latest news

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

ADILAdial Pharmaceuticals2025-05-15 08:30 EST

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ADILAdial Pharmaceuticals2025-05-13 08:30 EST

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

ADILAdial Pharmaceuticals2025-05-08 08:30 EST

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

ADILAdial Pharmaceuticals2025-05-02 11:48 EST

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Stock data

Close
4.80 USD
Market cap
5.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States